资源描述
恶性淋巴瘤免疫治疗进展,1,History of Immunotherapy,Elert E. Nature. 2013;504:S2-S3.,1796: First use of immunotherapy, Jenner smallpox vaccine,1976: BCG vaccine for bladder cancer,1863: Connection between immunotherapy and cancer recognized,1985: Interferon first approved for hairy cell leukemia,1992: IL-2 approved for RCC,1997: First mAb for cancer approved, rituximab,2008: First cancer vaccine approved for RCC,2010: Sipuleucel-T approved for prostate cancer,2011: CTLA-4 inhibitor approved for melanoma,2014-2015: PD-1 inhibitors approved for melanoma, squamous NSCLC,2015: First oncolytic virus approved for melanoma,2016: PD-1 inhibitor approved for cHL PD-L1 inhibitor approved for UC,2,霍奇金淋巴瘤：背景,HL, Classic type, 95% past 40 years, 86% will live 5 years after diagnosis. 20% to 30% relapse after initial treatment or will not respond to therapy at all. Such patients: autologous stem-cell transplantation (ASCT). newer treatment regimen + brentuximab vedotin, many patients eventually worsens.,3,CBT治疗HL有效的机制 Roemer MG, Advani RH, Ligon AH, et al: PDL1 and PD-L2 genetic alterations dene classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34:2690-2697, 2016 .,Reed-Sternberg cells from genetic changes. Which result in an abundance of immune checkpoint molecules PD-L1 and PD-L2. cHL, PD-L1 and PD-L2 molecules were found in 97% of the 108 specimens tested response rates to PD-1 inhibitors are higher in classic HL than in any other type of cancer studied to date. CBT，checkpoint blockade therapy， (免疫)检查点阻滞治疗,4,CBT治疗HL有效的机制 Roemer MG, Advani RH, Ligon AH, et al: PDL1 and PD-L2 genetic alterations dene classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34:2690-2697, 2016 .,病理类型影响PD-L1、2表达 86% nodular sclerosis, 11% mixed-cellularity 3% not otherwise specied. 病期影响基因扩增、预后 Amplication of 9p24.1 is more common in patients with advanced stage disease （III/IV） and associated with shorter PFS in this series.,5,
展开阅读全文